Alzheimer disease (AD) is a progressive, neurodegenerative disease characterised in life by
cognitive decline and behavioural symptoms and post-mortem by the neuropathological …

Accumulation, aggregation and deposition of A β peptides are pathological hallmarks in the
brains of individuals affected by A lzheimer's disease (AD) or by cerebral β‐amyloid …

Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) plaques,
senile plaque. The Aβ peptide is cleaved from amyloid precursor protein (APP) by β …

Transgenic mice that express mutant amyloid precursor protein (APPsi) using tet-Off vector
systems provide an alternative model for assessing short-and long-term effects of Aβ …

In the wake of genomics, metabolomics characterizes the small molecular metabolites
revealing the phenotypes induced by gene mutants. To address the metabolic signatures in …

Amyloid-β (Aβ) deposition in the brain vasculature results in cerebral amyloid angiopathy
(CAA), which occurs in about 80% of Alzheimer's disease (AD) patients. While Aβ42 …

Alzheimer's disease (AD) is an etiologically heterogeneous disorder. While many genes
have been found to be associated with Early and Late onset AD, a large portion of the …

Neurodegenerative foldopathies are characterized by aberrant folding of diseased modified
proteins, which are major constituents of the intracellular and extracellular lesions. These …

Contactin associated protein (Caspr), an adhesion molecule, plays roles in formation of
paranodal junctions in myelinated axons, neurite outgrowth, synaptic plasticity in nervous …

The study of Alzheimer's Disease (AD) has been hindered by the absence of animal models
of late-onset/age-related AD (also termed sporadic AD)(95% of AD cases) since current …